Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 06, 2024 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

NEW YORK, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives...
December 01, 2023 07:30 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)

Posters with new preclinical data on the pharmacokinetic and pharmacodynamic behavior of OV329 support its profile as a potential best-in-class GABA aminotransferase inhibitor Disease models provide...
November 03, 2023 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates

Received a $30 million payment from Ligand for the sale of a 13% interest in the potential future royalties and milestone payments owed to Ovid for soticlestat The Company extended its expected cash...
October 18, 2023 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026

Ligand will receive 13% of all soticlestat royalties and milestone payments owed to OvidOvid secures a $30 million non-dilutive capital infusion from Ligand, which Ovid expects to extend its cash...
October 10, 2023 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics to Present at the Jefferies Biotech CNS/Neuro Summit

NEW YORK, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies...
September 26, 2023 07:30 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics to Host Investor Event - R&D Day on Monday, October 2, 2023

NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies...
September 20, 2023 07:30 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference

NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies...
August 30, 2023 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics to Participate in Upcoming September Investor Conferences

NEW YORK, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies...
August 04, 2023 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates

Completed single ascending dose (SAD) portion of Phase 1 trial evaluating OV329, a potential next-generation GABA-aminotransferase inhibitor Executed equity investment and initiated collaboration with...
August 01, 2023 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2023

NEW YORK, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies...